Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinoma.
Bone metastasis
Lung cancer
Periostin
Serum biomarker
Survival
Journal
Journal of bone oncology
ISSN: 2212-1366
Titre abrégé: J Bone Oncol
Pays: Netherlands
ID NLM: 101610292
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
18
12
2020
revised:
07
04
2021
accepted:
11
04
2021
entrez:
21
6
2021
pubmed:
22
6
2021
medline:
22
6
2021
Statut:
epublish
Résumé
More than 35% of lung adenocarcinoma patients have bone metastases at diagnosis and have a poor survival. Periostin, a carboxylated matrix protein, mediates lung cancer cell dissemination by promoting epithelial-mesenchymal transition, and is involved in bone response to mechanical stress and bone formation regulation. This suggests that periostin may be used as a biomarker to predict survival in lung cancer patients. Serum periostin was assessed at diagnosis in a prospective cohort of 133 patients with lung adenocarcinoma of all stages. Patients were divided into localized and bone metastatic groups. Both groups were matched to healthy controls. Survival analysis and Cox proportional hazards models were conducted in the total population and in bone metastatic group. The median serum periostin level was higher in bone metastatic (n = 67; median: 1752 pmol/L) than in the localized group (n = 66; 861 pmol/L; p < 0.0001). Patients with high periostin (>median) had a poorer overall survival in the whole population (33.3 weeks vs. NR; p < 0.0001) and the bone metastatic group (24.4 vs. 66.1 weeks; p < 0.001). In multivariate analysis, patients with high periostin had increased risk of death (HR = 2.09, 95%CI [1.06-4.13]; p = 0.03). This was also found in the bone metastatic group (HR = 3.62, 95%CI [1.74-7.52]; p = 0.0005). Immunohistochemistry on bone metastasis biopsies showed periostin expression in the bone matrix and nuclear and cytoplasmic staining in cancer cells. Serum periostin was an independent survival biomarker in all-stage and in bone metastatic lung adenocarcinoma patients. IHC data suggest that periostin might be induced in cancer cells in bone metastatic niche in addition to bone microenvironment expression.
Identifiants
pubmed: 34150488
doi: 10.1016/j.jbo.2021.100364
pii: S2212-1374(21)00018-X
pmc: PMC8190464
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100364Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Clin Exp Allergy. 2016 Oct;46(10):1303-14
pubmed: 27237923
Oncol Lett. 2013 Dec;6(6):1595-1603
pubmed: 24273600
J Histochem Cytochem. 2008 Aug;56(8):753-64
pubmed: 18443362
Cancer Res. 2006 Jul 15;66(14):6928-35
pubmed: 16849536
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14170-5
pubmed: 20660732
Life Sci. 2017 Aug 1;182:10-21
pubmed: 28601389
Bonekey Rep. 2014 Oct 01;3:580
pubmed: 25328676
Physiol Rep. 2017 Jul;5(13):
pubmed: 28701525
Oncotarget. 2017 Jul 15;8(37):62248-62260
pubmed: 28977942
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Mol Cell Endocrinol. 2016 Sep 5;432:75-82
pubmed: 26721738
Breast Cancer Res Treat. 2020 Apr;180(2):515-524
pubmed: 32040688
J Allergy Clin Immunol. 2006 Jul;118(1):98-104
pubmed: 16815144
Clin Cancer Res. 2008 Nov 15;14(22):7430-7
pubmed: 19010860
Oncotarget. 2017 Mar 21;8(12):18746-18753
pubmed: 27816968
J Biol Chem. 2006 Jul 14;281(28):19700-8
pubmed: 16702213
J Clin Lab Anal. 2018 Feb;32(2):
pubmed: 28493527
J Bone Miner Res. 2017 Nov;32(11):2232-2238
pubmed: 28766739
Cancer Cell. 2008 Jan;13(1):58-68
pubmed: 18167340
Lung Cancer. 2012 May;76(2):183-90
pubmed: 22079858
Ann Transl Med. 2020 Apr;8(7):482
pubmed: 32395526
J Cell Physiol. 2020 Mar;235(3):2800-2808
pubmed: 31517399
World J Gastroenterol. 2015 Mar 7;21(9):2605-13
pubmed: 25759527
N Engl J Med. 2011 Sep 22;365(12):1088-98
pubmed: 21812663
Respir Med. 2015 Jun;109(6):708-15
pubmed: 25869478
Cancer Lett. 2009 Aug 28;281(2):213-9
pubmed: 19328625
Respir Res. 2018 Jun 7;19(1):112
pubmed: 29879994
Bone. 2018 Mar;108:202-209
pubmed: 29337225
J Bone Miner Res. 1997 Apr;12(4):683-90
pubmed: 9101381
J Biol Chem. 2009 Dec 18;284(51):35939-50
pubmed: 19837663
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15048-53
pubmed: 22927401
Cell Physiol Biochem. 2016;38(3):1199-208
pubmed: 26982182
J Bone Miner Res. 2010 Nov;25(11):2313-23
pubmed: 20499368
Tumour Biol. 2017 May;39(5):1010428317698367
pubmed: 28459197
Oncol Rep. 2016 Nov;36(5):2745-2754
pubmed: 27633896
Nature. 2011 Dec 07;481(7379):85-9
pubmed: 22158103
Mayo Clin Proc. 2019 Aug;94(8):1623-1640
pubmed: 31378236